SCHEMBL20567786

SCHEMBL20567786

CC(C)(C)OC(=O)N1CCN(Cc2ccc(C(F)(F)F)c(C(=O)NN)c2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLS O94925 2/20 0.45
FAAH O00519 1/20 0.45
MGLL Q99685 2/20 0.44
IDO1 P14902 1/20 0.43
TDO2 P48775 1/20 0.43
IDO2 Q6ZQW0 1/20 0.43
VEGFA P15692 1/20 0.43
EGLN1 Q9GZT9 1/20 0.43
ACKR3 P25106 2/20 0.42
EPHX2 P34913 1/20 0.41
MAPT P10636 1/20 0.41
TBK1 Q9UHD2 2/20 0.41
PLA2G7 Q13093 1/20 0.41
ABHD6 Q9BV23 1/20 0.41
RORC P51449 2/20 0.41
RXFP1 Q9HBX9 1/20 0.41
MEN1 O00255 1/20 0.40
CYP2C19 P33261 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20567000 0.88 ALDH1A1 (0.45) GLSFAAHMGLLIDO1TDO2
SCHEMBL25487261 0.86 IDO1 (0.45) GLSFAAHIDO1TDO2IDO2
SCHEMBL20571160 0.85 FAAH (0.49) FAAHMGLLMEN1KMT2A
SCHEMBL20567707 0.83 FAAH (0.46) GLSFAAHMGLLIDO1TDO2
SCHEMBL27677145 0.83 FAAH (0.47) GLSFAAHMGLLIDO1TDO2
SCHEMBL18064777 0.83 IDO1 (0.46) GLSFAAHMGLLIDO1TDO2
SCHEMBL20566886 0.83 FAAH (0.50) FAAHMGLLIDO1TDO2IDO2
SCHEMBL20567152 0.82 FAAH (0.48) GLSFAAHMGLLIDO1TDO2
SCHEMBL2544648 0.81 PREP (0.51) GLSFAAHMGLLIDO1TDO2
SCHEMBL20503440 0.79 MGLL (0.52) MGLLMAPTPLA2G7ABHD6RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12258340-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2025-03-25 US disclosed
CN-116473965-A Pyrazole MAGL inhibitors H.隆德贝克有限公司 2023-07-25 CN disclosed
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2023-07-13 US disclosed
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2023-07-13 US disclosed
EP-4198024-A1 PYRAZOLE MAGL INHIBITORS H. Lundbeck A/S (DK) 2023-06-21 EP disclosed
EP-4198024-A1 PYRAZOLE MAGL INHIBITORS H. Lundbeck A/S (DK) 2023-06-21 EP disclosed
US-11655217-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2023-05-23 US disclosed
US-11655217-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2023-05-23 US disclosed
CN-110678456-B Pyrazole MAGL inhibitors H.隆德贝克有限公司 2023-05-02 CN disclosed
EP-3630744-B1 PYRAZOLE MAGL INHIBITORS H LUNDBECK AS (DK) 2023-01-25 EP disclosed
US-20210053960-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2021-02-25 US disclosed
US-20210053960-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2021-02-25 US disclosed
US-10927105-B1 Pyrazole MAGL inhibitors LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) 2021-02-23 US disclosed
US-10927105-B1 Pyrazole MAGL inhibitors LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) 2021-02-23 US disclosed
EP-3630744-A1 PYRAZOLE MAGL INHIBITORS Lundbeck La Jolla Research Center, Inc. (US) 2020-04-08 EP disclosed
CN-110678456-A Pyrazole MAGL inhibitors 隆德贝克拉荷亚研究中心有限公司 2020-01-10 CN disclosed
US-10266497-B2 Pyrazole MAGL inhibitors ABIDE THERAPEUTICS, INC. (US) 2019-04-23 US disclosed
US-10266497-B2 Pyrazole MAGL inhibitors ABIDE THERAPEUTICS, INC. (US) 2019-04-23 US disclosed
WO-2018217805-A1 PYRAZOLE MAGL INHIBITORS ABIDE THERAPEUTICS, INC. (US) 2018-11-29 WO disclosed
US-20180339970-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2018-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180339970-A1 PYRAZOLE MAGL INHIBITORS MGLL, PNLIP, LPL GLS 1635/4885FAAH 33/4885MGLL 1/4885
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS MGLL, PNLIP, LPL GLS 1635/4885FAAH 33/4885MGLL 1/4885
US-12258340-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL GLS 1946/4885FAAH 32/4885MGLL 1/4885
US-10266497-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL GLS 1635/4885FAAH 33/4885MGLL 1/4885
US-20210053960-A1 PYRAZOLE MAGL INHIBITORS MGLL, PNLIP, LPL GLS 1635/4885FAAH 33/4885MGLL 1/4885
US-11655217-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL GLS 1946/4885FAAH 32/4885MGLL 1/4885
US-10927105-B1 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL GLS 1635/4885FAAH 33/4885MGLL 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.